Literature DB >> 9888423

Regulation of human leukocyte antigen expression in human conjunctival epithelium.

K Tsubota1, K Fukagawa, T Fujihara, S Shimmura, I Saito, K Saito, T Takeuchi.   

Abstract

PURPOSE: To demonstrate that interferon-gamma (IFN-gamma) is the key cytokine responsible for the upregulation of HLA-DR antigen in conjunctival epithelial cells of Sjogren syndrome (SS) patients.
METHODS: Flow cytometry of conjunctival epithelial cells from SS and non-SS dry eye patients was performed for the quantification of HLA-DR surface expression. With a conjunctival epithelial cell line (ChWK), HLA-DR regulation by various cytokines was evaluated, and confocal immunocytochemical and western blot analyses were performed to evaluate the activation of nuclear factorkappa B (NF-kappaB) and signal transducers and activators of transcription 1 and 3 (STAT1 and STAT3, respectively).
RESULTS: HLA-DR expression was upregulated in conjunctival epithelial cells of SS patients but not in non-SS dry eye patient or healthy control subject. IFN-gamma was the only cytokine that effectively upregulated HLA-DR expression in ChWK, which was synergistically enhanced by tumor necrosis factor-alpha (TNF-alpha). IFN-gamma induced the nuclear translocation of NF-kappaB, but did not activate STAT1 or STAT3 in ChWK.
CONCLUSIONS: Upregulation of HLA-DR antigen in the conjunctival epithelium of SS patients may be regulated by IFN-gamma through the activation of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888423

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

Review 1.  T helper cytokines in dry eye disease.

Authors:  Stephen C Pflugfelder; Rosa M Corrales; Cintia S de Paiva
Journal:  Exp Eye Res       Date:  2013-09-04       Impact factor: 3.467

2.  Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.

Authors:  Rodrigo Guimaraes de Souza; Zhiyuan Yu; Michael E Stern; Stephen C Pflugfelder; Cintia S de Paiva
Journal:  J Ocul Pharmacol Ther       Date:  2018-06-29       Impact factor: 2.671

3.  Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.

Authors:  Mehmet Ozgur Cubuk; Ahmet Yucel Ucgul; Armagan Ozgur; Kemal Ozulken; Erdem Yuksel
Journal:  Int Ophthalmol       Date:  2021-01-23       Impact factor: 2.031

Review 4.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 5.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

6.  Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: its effect on drug efflux and its regulation by adenoviral infection.

Authors:  Johnny J Yang; David K Ann; Ram Kannan; Vincent H L Lee
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

7.  Effects of Dry Eye Therapies on Environmentally Induced Ocular Surface Disease.

Authors:  Quianta L Moore; Cintia S De Paiva; Stephen C Pflugfelder
Journal:  Am J Ophthalmol       Date:  2015-04-11       Impact factor: 5.258

Review 8.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

Review 9.  The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research.

Authors:  Stephen C Pflugfelder; Cintia S de Paiva
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 12.079

10.  Characterization and short-term culture of cells recovered from human conjunctival epithelium by minimally invasive means.

Authors:  Hernán Martínez-Osorio; Margarita Calonge; Alfredo Corell; Roberto Reinoso; Antonio López; Itziar Fernández; Eloína Gutiérrez San José; Yolanda Diebold
Journal:  Mol Vis       Date:  2009-10-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.